Polyclonal antibodies for the treatment of COVID-19 infection
Polyclonal antibodies are very efficient and superior to monoclonal antibodies as a treatment option for bacterial or viral infectious diseases. French company XENOTHERA has developed a platform for the production of glyco-humanised polyclonal antibodies with high efficiency and optimised safety. Currently, XENOTHERA is working on the development of a new treatment against COVID-19 based on this technology. The product, XAV-19, is expected to treat patients suffering from moderate to severe pneumonia. The purpose of the EU-funded BRIGHT project is to prepare the product and complete all necessary actions for a phase 2 double-blind clinical trial to demonstrate its efficacy.
Field of science
- /medical and health sciences/health sciences/infectious disease/RNA virus/coronavirus
Call for proposal
See other projects for this call